|

HLX22 Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Shanghai Henlius Biotech2

Indications

  • Cancer2
  • HER2-low Hormone Receptor Positive Breast Cancer1
  • HER2-positive Gastric Cancer1
  • Monoclonal Antibody1
  • Gastric Cancer1

Other1 trial

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
Phase 2

Anaheim, California1 trial

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Los Angeles Cancer Network

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.